Literature DB >> 11085656

New insights in the cellular processing of platinum antitumor compounds, using fluorophore-labeled platinum complexes and digital fluorescence microscopy.

C Molenaar1, J M Teuben, R J Heetebrij, H J Tanke, J Reedijk.   

Abstract

The cellular distribution and processing pathways of two platinum compounds, modeling the antitumor drug cisplatin (cDDP) in human osteosarcoma (U2-OS) cells is reported. A [Pt(en)Cl] entity has been covalently linked to a carboxyfluorescein diacetate (CFDA) moiety and to a dinitrophenyl (DNP) moiety. The two different constructs were administered to living cell cultures that were analyzed using digital fluorescence microscopy. The non-fluorescent CFDA construct becomes fluorescent after cellular uptake and subsequent acetate hydrolysis by esterases, and is therefore suitable to monitor platinum in living cells; the DNP construct can be visualized by immunocytochemistry and consequently serves as a control. Both complexes were readily internalized by the cells, and localized throughout the whole cell. After 2-3 h the complex accumulated in the nucleus, but 6-8 h after incubation a punctuate staining of a cytoplasmic region was observed, that persisted and became more pronounced after 24 h. The overall fluorescence in the cell decreased over time, implying a secretion of the platinum complex. Surprisingly, the accumulation remained visible after 72 h. Co-localization experiments with a Golgi apparatus-selective stain indicate the involvement of Golgi vesicles in intracellular processing of cisplatin-derived complexes. Immunocytochemical studies, using the DNP derivative, resulted in very similar images as obtained with the CFDA construct. CFDA-boc (a non-platinum-containing fluorescein derivative) was used as control: a faint staining throughout the whole cell was observed. Cisplatin-resistant U2-OS/Pt cells showed staining patterns very similar to the U2-OS cells using both platinum constructs. This study illustrates that only a very small portion of the platinum complex eventually remains bound to DNA, as after 24 h no significant fluorescence could be observed in the nucleus. Cisplatin-derived complexes with fluorescent tags afford a new insight into the cellular processing of these complexes and therefore may contribute to further unraveling of the mechanism of platinum antitumor complexes.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11085656     DOI: 10.1007/s007750000153

Source DB:  PubMed          Journal:  J Biol Inorg Chem        ISSN: 0949-8257            Impact factor:   3.358


  21 in total

Review 1.  New clues for platinum antitumor chemistry: kinetically controlled metal binding to DNA.

Authors:  Jan Reedijk
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-24       Impact factor: 11.205

2.  The cellular distribution and oxidation state of platinum(II) and platinum(IV) antitumour complexes in cancer cells.

Authors:  Matthew D Hall; Carolyn T Dillon; Mei Zhang; Philip Beale; Zhonghou Cai; Barry Lai; Anton P J Stampfl; Trevor W Hambley
Journal:  J Biol Inorg Chem       Date:  2003-07-12       Impact factor: 3.358

3.  Synthesis, characterization, and photophysical properties of three platinum(II) complexes bearing fluorescent analogues of the Di-2-pyridylmethane ligand.

Authors:  Justin J Wilson; Juliana Fedoce Lopes; Stephen J Lippard
Journal:  Inorg Chem       Date:  2010-06-07       Impact factor: 5.165

4.  Spectrum of cellular responses to pyriplatin, a monofunctional cationic antineoplastic platinum(II) compound, in human cancer cells.

Authors:  Katherine S Lovejoy; Maria Serova; Ivan Bieche; Shahin Emami; Maurizio D'Incalci; Massimo Broggini; Eugenio Erba; Christian Gespach; Esteban Cvitkovic; Sandrine Faivre; Eric Raymond; Stephen J Lippard
Journal:  Mol Cancer Ther       Date:  2011-07-12       Impact factor: 6.261

Review 5.  Binding of kinetically inert metal ions to RNA: the case of platinum(II).

Authors:  Erich G Chapman; Alethia A Hostetter; Maire F Osborn; Amanda L Miller; Victoria J DeRose
Journal:  Met Ions Life Sci       Date:  2011

6.  Platinum compounds for high-resolution in vivo cancer imaging.

Authors:  Miles A Miller; Bjorn Askevold; Katherine S Yang; Rainer H Kohler; Ralph Weissleder
Journal:  ChemMedChem       Date:  2014-02-06       Impact factor: 3.466

7.  Investigation of polymer electrolyte membrane chemical degradation and degradation mitigation using in situ fluorescence spectroscopy.

Authors:  Venkateshkumar Prabhakaran; Christopher G Arges; Vijay Ramani
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-04       Impact factor: 11.205

8.  Dinuclear platinum complexes with N, N'-bis(aminoalkyl)-1,4-diaminoanthraquinones as linking ligands. Part II. Cellular processing in A2780 cisplatin-resistant human ovarian carcinoma cells: new insights into the mechanism of resistance.

Authors:  Ganna V Kalayda; Bart A J Jansen; Chris Molenaar; Peter Wielaard; Hans J Tanke; Jan Reedijk
Journal:  J Biol Inorg Chem       Date:  2004-04-08       Impact factor: 3.358

9.  Dinuclear platinum complexes with N, N'-bis(aminoalkyl)-1,4-diaminoanthraquinones as linking ligands. Part I. Synthesis, cytotoxicity, and cellular studies in A2780 human ovarian carcinoma cells.

Authors:  Bart A J Jansen; Peter Wielaard; Ganna V Kalayda; Maura Ferrari; Chris Molenaar; Hans J Tanke; Jaap Brouwer; Jan Reedijk
Journal:  J Biol Inorg Chem       Date:  2004-04-08       Impact factor: 3.358

10.  Evaluation of fluorophore-tethered platinum complexes to monitor the fate of cisplatin analogs.

Authors:  Justin C Jagodinsky; Agnieszka Sulima; Yiqi Cao; Joanna E Poprawski; Burchelle N Blackman; John R Lloyd; Rolf E Swenson; Michael M Gottesman; Matthew D Hall
Journal:  J Biol Inorg Chem       Date:  2015-09-01       Impact factor: 3.358

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.